Compare Citius Pharmaceuticals Inc (CTXR) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VanEck Vietnam ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while VanEck Vietnam ETF trades at $17.35. The key difference: VanEck Vietnam ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VNM | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $19.80 |
52-Week Low | $0.53 | $15.35 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
VNM trades at $17.53, down 2.5% today, with a bearish technical outlook as moving averages signal strong selling pressure. The stock's key financial ratios are currently unavailable, limiting fundamental assessment. Recent news highlights Vietnam ETF underperformance and regional economic pressures, including power grid strain from heatwaves and geopolitical tensions affecting emerging markets.
The outlook remains cautious due to technical weakness and emerging market headwinds. Investment opportunities hinge on Vietnam's economic recovery and foreign institutional flows post-FTSE Russell reclassification, but risks include persistent underperformance versus global equities and domestic infrastructure challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
